Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Maintenance vs Observation in CLL (Mabtenance)
NCT01118234Phase 3Completed
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Start
- Dec 2009
- Primary completion
- Feb 2018
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia (CLL) comparing Rituximab with Observation (2 arms). Primary endpoint: Progression Free Survival at 48 months. Started Dec 2009; status: completed.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01118234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01118234.